Ottawa – Health Canada has approved the first vaccine for respiratory syncytial virus (RSV) for adults age 60 and over. Manufacturer GSK says the federal agency has approved its new vaccine called Arexvy. Doctors have been calling for an RSV vaccine for seniors because although the virus is common, older people are much more likely to become severely ill and …